InvAscent and Morgan Stanley Private Equity Asia have invested INR 10,000 million in Maiva Pharma to expand its manufacturing capabilities for sterile injectables in response to growing global demand.

Information on the Target

Maiva Pharma, founded in 1993 and based in Bengaluru, is recognized as India's second-largest contract development and manufacturing organization (CDMO) specializing in injectables. The company operates a state-of-the-art manufacturing facility located in Hosur, which is approved by regulatory authorities including the US FDA, EU GMP, and ANVISA. Maiva has established a strong reputation for its commitment to quality, adherence to compliance standards, and ethical business practices in key markets such as the US, Europe, Canada, Australia, and Latin America. With a diverse portfolio exceeding 75 products, Maiva serves more than 40 customers across various global regions, focusing on sterile injectables in vials and lyophilized forms.

Industry Overview in India

The pharmaceutical industry in India is among the largest in the world, known for its extensive range of generic drugs and growing capabilities in contract manufacturing. With a projected market value of USD 55 billion by 2024, the industry is experiencing significant growth driven by increased healthcare expenditure and rising demand for quality medications. India is not only a supplier to developed markets but is also gaining traction in emerging markets due to its competitive advantages in production costs and regulatory compliance.

Furthermore, the Indian CDMO sector is witnessing substantial investment and innovation as companies optimize their manufacturing processes. The growing complexity of drug formulations, particularly sterile injectables, necessitates advanced manufacturing capabilities